Checkmating tumors

November 28, 2018, Max Delbrück Center for Molecular Medicine
Microscopic image of tumor cells in which Ezh2 activity is inhibited (red) within a mouse lung and surrounded by immune cells (green). Credit: Michela Serresi, MDC

Chess and cancer research have one thing in common: It takes strategy to defeat the opponent. And that's exactly what scientists at the MDC are doing. They are seeking to selectively make only those cancer cells aggressive that would otherwise evade chemotherapy—and then lure them into a trap.

In chemotherapy, cytostatics—substances halting —prevent from growing and induce cellular death. This approach often leads to success but has a number of drawbacks. It has a negative effect on , and may also cause significant side effects in some patients. What's more, in the case of very , some cancer usually survive the therapy. "The remaining cancer cells are especially dangerous because they are altered in such a way that physicians often no longer know what type of cancer cells they are dealing with," explains Dr. Gaetano Gargiulo, head of the Molecular Oncology research group at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC). This makes it difficult to choose the right substances for further treatment.

Being prepared for the opponent's next move

In a certain form of non-small cell lung cancer, the chemotherapy frequently results in altered cancer cells that are almost untreatable. Those developing new treatments must keep this possibility in mind. "Like a good chess player, we must think several moves ahead instead of just reacting to the present situation," says Gargiulo. Together with his team and researchers under Professor Maarten van Lohuizen of the Netherlands Cancer Institute in Amsterdam, he has tested how this might work on mice that were injected with cells of a special form of non-small cell lung cancer.

In this form of non-, the cancer cells produce large quantities of an enzyme called Ezh2. The enzyme represses a number of , which normally stop cells from multiplying out of control. Agents that inhibit this enzyme and thus reactivate the tumor suppressor genes are currently being tested in clinical studies. "In our mice, this agent initially worked as expected and inhibited the multiplication of tumor cells, thus keeping the cancer in check," says Michela Serresi, the lead author of the publication and team leader associated with Gargiulo's research group.

But the researchers had also expected the agent to lose its effect over time. "Interestingly, there always developed an inflammatory situation that in turn supported tumor growth," says Serresi. The remaining cancer cells thus became even more aggressive as a result of the treatment.

Making cancer cells aggressive—and then moving in for checkmate

This is precisely where the MDC researchers are focusing their efforts. They are intentionally sending the tumor cells down this path—and setting them up for a trap. "Although the cells may be extremely aggressive once they are resistant to the Ezh2 inhibitor, they are dependent on the inflammatory situation," explains Gargiulo. "If we can foresee this development, similar to the way skilled chess players think through the possible moves their opponents might make, and even deliberately force it to occur, we can also selectively combat it." Therefore, in the second step of the therapy, the researchers administered the mice an anti-inflammatory substance—putting the cancer cells in checkmate.

However, it is still a long way to go before patients will see benefits from these new treatment strategies. "If we intentionally make cells more aggressive, we have to know exactly what we're doing," says Gargiulo, adding that, for example, it would be necessary to search for biomarkers that enable clinical scientists to clearly predict in which patients this strategy will actually be effective. "We first have to gather sufficient data and experience in the lab before we can even think about testing this treatment strategy on patients," emphasizes Gargiulo.

Explore further: Proposed cancer treatment may boost lung cancer stem cells, study warns

More information: Michela Serresi et al. (2018): "Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities." Journal of Experimental Medicine. DOI: 10.1084/jem.20180801

Related Stories

Proposed cancer treatment may boost lung cancer stem cells, study warns

November 20, 2018
Epigenetic therapies—targeting enzymes that alter what genes are turned on or off in a cell—are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant. Researchers at Boston ...

Reducing NOVA1 gene helps prevent tumor growth in most common type of lung cancer

August 6, 2018
Researchers have identified a gene that when inhibited or reduced, in turn, reduced or prevented human non-small cell lung cancer tumors from growing.

New drug technology may improve treatment options for aggressive types of breast cancer

June 20, 2018
Purdue University researchers have developed a new technology that may change how one of the most aggressive types of breast cancer is treated.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

New study discovers "killer peptide" that eliminates resistant cancer cells

August 7, 2017
A new study by University of Kentucky Markey Cancer Center researchers shows that when therapy-sensitive cancer cells die, they release a "killer peptide" that can eliminate therapy-resistant cells.

Genetic targets to chemo-resistant breast cancer identified

October 3, 2017
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.

Recommended for you

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Nov 28, 2018
hype hype and nothing but hype

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.